注意欠陥多動性障害（ADHD）治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-14806 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、103ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、注意欠陥多動性障害（ADHD）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。注意欠陥多動性障害（ADHD）治療の種類別市場規模（覚醒剤、非刺激剤）、用途別市場規模（小児・青年、成人）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、UCB、Novartis、GSK、Hisamitsu、Eli Lilly、Purdue Pharma、Mallinckrodt、Johnson & Johnson、Takeda、Impax Laboratories ・地域別グローバル市場分析 2015年-2020年 ・注意欠陥多動性障害（ADHD）治療の北米市場（アメリカ、カナダ、メキシコ） ・注意欠陥多動性障害（ADHD）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・注意欠陥多動性障害（ADHD）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・注意欠陥多動性障害（ADHD）治療の南米市場（ブラジル、アルゼンチン） ・注意欠陥多動性障害（ADHD）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：覚醒剤、非刺激剤 ・用途別分析：小児・青年、成人 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales will be xx in 2020 from Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market has been segmented into:
Stimulants
Non-stimulants

By Application, Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics has been segmented into:
Pediatric and Adolescents
Adults

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Analysis
Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics are:
Pfizer
UCB
Novartis
GSK
Hisamitsu
Eli Lilly
Purdue Pharma
Mallinckrodt
Johnson & Johnson
Takeda
Impax Laboratories
Among other players domestic and global, Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Overview
1.1 Product Overview and Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
1.2 Classification of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Type
1.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type in 2019
1.2.3 Stimulants
1.2.4 Non-stimulants
1.3 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Application
1.3.1 Overview: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Pediatric and Adolescents
1.3.3 Adults
1.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Regions
1.4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Impact
1.5.1 COVID-19 Potential Implications for the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 UCB
2.2.1 UCB Details
2.2.2 UCB Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 UCB SWOT Analysis
2.2.4 UCB Product and Services
2.2.5 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GSK SWOT Analysis
2.4.4 GSK Product and Services
2.4.5 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Hisamitsu
2.5.1 Hisamitsu Details
2.5.2 Hisamitsu Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Hisamitsu SWOT Analysis
2.5.4 Hisamitsu Product and Services
2.5.5 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Eli Lilly Product and Services
2.6.4 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Purdue Pharma
2.7.1 Purdue Pharma Details
2.7.2 Purdue Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Purdue Pharma Product and Services
2.7.4 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Mallinckrodt
2.8.1 Mallinckrodt Details
2.8.2 Mallinckrodt Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Mallinckrodt Product and Services
2.8.4 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Johnson & Johnson Product and Services
2.9.4 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Takeda
2.10.1 Takeda Details
2.10.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Takeda Product and Services
2.10.4 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.11 Impax Laboratories
2.11.1 Impax Laboratories Details
2.11.2 Impax Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Impax Laboratories Product and Services
2.11.4 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share
3.2.2 Top 10 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Market Share by Regions
4.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
5.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
5.2 USA Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
6.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
7.2 China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
8.1 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Countries
9.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Type (2019-2024)
10.3 Stimulants Revenue Growth Rate (2015-2025)
10.4 Non-stimulants Revenue Growth Rate (2015-2025)
11 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment by Application
11.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Application (2019-2024)
11.3 Pediatric and Adolescents Revenue Growth (2015-2020)
11.4 Adults Revenue Growth (2015-2020)
12 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Forecast (2021-2025)
12.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Forecast (2021-2025)
12.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Pfizer Corporate Information, Location and Competitors
Table 7. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 8. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 9. Pfizer SWOT Analysis
Table 10. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 11. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. UCB Corporate Information, Location and Competitors
Table 13. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 14. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 15. UCB SWOT Analysis
Table 16. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 17. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Novartis Corporate Information, Location and Competitors
Table 19. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 20. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 21. Novartis SWOT Analysis
Table 22. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 23. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. GSK Corporate Information, Location and Competitors
Table 25. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 26. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 27. GSK SWOT Analysis
Table 28. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 29. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Hisamitsu Corporate Information, Location and Competitors
Table 31. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 32. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 33. Hisamitsu SWOT Analysis
Table 34. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 35. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Eli Lilly Corporate Information, Location and Competitors
Table 37. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 38. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 39. Eli Lilly SWOT Analysis
Table 40. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 41. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Purdue Pharma Corporate Information, Location and Competitors
Table 43. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 44. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 45. Purdue Pharma SWOT Analysis
Table 46. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 47. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Mallinckrodt Corporate Information, Location and Competitors
Table 49. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 50. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 51. Mallinckrodt SWOT Analysis
Table 52. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 53. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Johnson & Johnson Corporate Information, Location and Competitors
Table 55. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 56. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 57. Johnson & Johnson SWOT Analysis
Table 58. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 59. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Takeda Corporate Information, Location and Competitors
Table 61. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 62. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 63. Takeda SWOT Analysis
Table 64. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 65. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Impax Laboratories Corporate Information, Location and Competitors
Table 67. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Major Business
Table 68. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 69. Impax Laboratories SWOT Analysis
Table 70. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
Table 71. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 73. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players (2015-2020)
Table 74. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 75. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Regions (2015-2020)
Table 76. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
Table 77. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 78. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 80. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2015-2020)
Table 81. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 84. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 85. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Type (2015-2020)
Table 86. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Forecast by Type (2021-2025)
Table 87. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2015-2020)
Table 88. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application (2015-2020)
Table 89. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Forecast by Application (2021-2025)
Table 90. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Picture
Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type in 2019
Figure 3. Stimulants Picture
Figure 4. Non-stimulants Picture
Figure 5. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application in 2019
Figure 6. Pediatric and Adolescents Picture
Figure 7. Adults Picture
Figure 8. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share in 2019
Figure 17. Global Top 10 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 21. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Regions in 2018
Figure 22. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 23. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 28. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries in 2019
Figure 29. USA Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries in 2019
Figure 34. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. UK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries in 2019
Figure 41. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 47. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries in 2019
Figure 48. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Type (2015-2020)
Figure 57. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Type in 2019
Figure 58. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Type (2021-2025)
Figure 59. Global Stimulants Revenue Growth Rate (2015-2020)
Figure 60. Global Non-stimulants Revenue Growth Rate (2015-2020)
Figure 61. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application (2015-2020)
Figure 62. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application in 2019
Figure 63. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Application (2021-2025)
Figure 64. Global Pediatric and Adolescents Revenue Growth Rate (2015-2020)
Figure 65. Global Adults Revenue Growth Rate (2015-2020)
Figure 66. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 70. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 72. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel

---